Torsdag 26 December | 13:21:07 Europe / Stockholm

Kalender

Tid*
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-01 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2024-04-30 - Årsstämma
2024-04-04 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-08-01 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-04-28 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2023-04-27 - Årsstämma
2023-03-30 - Bokslutskommuniké 2022
2022-11-23 - Extra Bolagsstämma 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-11 - Kvartalsrapport 2022-Q1
2022-04-04 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2022-04-01 - Årsstämma
2022-03-10 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-11-15 - Extra Bolagsstämma 2021
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-12 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2021-04-29 - Årsstämma
2021-03-17 - Bokslutskommuniké 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-14 - Årsstämma
2020-03-20 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2020-03-11 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-03-19 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2019-03-18 - Årsstämma
2019-02-22 - Bokslutskommuniké 2018
2018-11-08 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-16 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2018-04-13 - Årsstämma
2018-03-08 - Bokslutskommuniké 2017
2017-11-07 - Kvartalsrapport 2017-Q3
2017-05-04 - Kvartalsrapport 2017-Q1
2017-04-24 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2017-04-21 - Årsstämma
2017-03-15 - Bokslutskommuniké 2016
2016-11-03 - Kvartalsrapport 2016-Q3
2016-08-04 - Kvartalsrapport 2016-Q2
2016-05-04 - Kvartalsrapport 2016-Q1
2016-04-15 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2016-04-14 - Årsstämma
2016-03-16 - Bokslutskommuniké 2015
2015-11-06 - Kvartalsrapport 2015-Q3
2015-08-10 - Kvartalsrapport 2017-Q2
2015-08-07 - Kvartalsrapport 2015-Q2
2015-05-05 - Kvartalsrapport 2015-Q1
2015-04-13 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2015-04-10 - Årsstämma
2015-03-18 - Bokslutskommuniké 2014
2014-11-07 - Kvartalsrapport 2014-Q3
2014-08-08 - Kvartalsrapport 2014-Q2
2014-05-06 - Kvartalsrapport 2014-Q1
2014-04-11 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2014-04-10 - Årsstämma
2014-03-19 - Bokslutskommuniké 2013
2013-11-08 - Kvartalsrapport 2013-Q3
2013-08-02 - Kvartalsrapport 2013-Q2
2013-05-07 - Kvartalsrapport 2013-Q1
2013-04-17 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2013-04-16 - Årsstämma
2013-03-19 - Bokslutskommuniké 2012
2013-02-26 - Extra Bolagsstämma 2013
2012-11-20 - Kvartalsrapport 2012-Q3
2012-08-23 - Kvartalsrapport 2012-Q2
2012-05-25 - Kvartalsrapport 2012-Q1
2012-04-18 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2012-04-17 - Årsstämma
2012-03-19 - Bokslutskommuniké 2011
2011-11-24 - Kvartalsrapport 2011-Q3
2011-08-25 - Kvartalsrapport 2011-Q2
2011-05-25 - Kvartalsrapport 2011-Q1
2011-04-07 - Årsstämma
2011-03-17 - X-dag ordinarie utdelning BIOPOR 0.00 DKK
2010-04-21 - X-dag ordinarie utdelning BIOPOR 0.00 DKK

Beskrivning

LandDanmark
ListaSmall Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
BioPorto är verksamt inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.
2022-11-03 17:00:00

November 3, 2022
News release

BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call

COPENHAGEN, DENMARK and BOSTON, MA, USA, November 3, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of kidney injury, announced today that in connection with the release of its Interim Report for the third quarter of 2022, the Company’s management team will host an online investor presentation on November 9, 2022 at 14:00 Central European Time / 8:00 Eastern Time via HC Andersen Capital.

Investors interested in attending the webcast may register at:

https://hca.videosync.fi/bioporto-presentation-q3-interim-9-nov-2022/register.

A separate analyst call will be held on November 9, 2022 at 16:00 Central European Time / 10:00 Eastern Time, with details as follows:

Denmark: +45 8025 0765
International: +1 412 317 5180
US: +1 844 825 9789
Conference ID: 10172482
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1577608&tp_key=ea0f8a8f79

Investor Relations Contacts

Tim Eriksen, EU Investor Relations, Zenith Advisory, +45 4529 0000, investor@bioporto.com
Ashley Robinson, US Investor Relations, LifeSci Advisors, +1 617 430 7577, arr@lifesciadvisors.com

About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship product is The NGAL TestTM, which has been designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The NGAL Test is CE marked and registered in a number of countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.